Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
WRAL Investigates: Why some veterinarians face minor charges for deadly mistakes
Recommended
Map shows parts of western NC open for tourism
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Knight Therapeutics Inc
(OP:
KHTRF
)
4.040
UNCHANGED
Last Price
Updated: 9:57 AM EDT, Oct 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Knight Therapeutics Inc
Is Ardelyx is A Buy After Slip in Early 2022
November 21, 2022
Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them
Via
MarketBeat
Exposures
Product Safety
Knight Therapeutics Secures Rights To Rigel's Fostamatinib In Latin America
May 24, 2022
Knight Therapeutics Inc. (TSX: GUD) (OTC: KHTRF)
Via
Benzinga
Puma Biotech's Nerlynx Wins Canadian Approval In HER2-Positive Metastatic Breast Cancer
July 06, 2021
Health Canada has approved Puma Biotechnology Inc's (NASDAQ: PBYI) Nerlynx (neratinib) in combination with capecitabine for metastatic HER2-overexpressed/amplified...
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.